Abstracts Archive - Page 2280 of 2425 - ACR Meeting Abstracts

Abstract Number: 2125 • 2012 ACR/ARHP Annual Meeting
Response to Methotrexate Plus Prednisone in Camera II Using a Multi-Biomarker Disease Activity (Vectra^TMDA) Test and DAS28-ESR
J.W.J. Bijlsma¹, M. Verhoef-Jurgens², M.F. Bakker¹, J.W.G. Jacobs¹, F.P.J.G. Lafeber¹, P.M.J. Welsing³, G. Cavet⁴, D. Chernoff⁴ and D.J. Haney⁴, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology, F02.127, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Crescendo Bioscience, Inc., South San Francisco, CA
Background/Purpose: The CAMERA II study (Computer Assisted Management in Early RA) demonstrated that the addition of prednisone to a MTX-based tight control strategy increased effectiveness…
Abstract Number: 2126 • 2012 ACR/ARHP Annual Meeting
Changes of Serological Markers in the Course of Traditional and Biological Disease Modifying Therapy of Rheumatoid Arthritis
Christoph Böhler¹, Helga Radner², Josef S. Smolen³ and Daniel Aletaha⁴, ¹Department of Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine III; Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁴Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid factor (RF) and antibodies against citrullinated peptides (ACPA) are established markers in the diagnostic approach to rheumatoid arthritis (RA). Both auto-antibodies (AAB) also…
Abstract Number: 2127 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA) Patients Discordant for Rheumatoid Factor and Anti-CCP Positivity Have Different Clinical and Laboratory Features Than RA Patients Seropositive or Seronegative for Both Markers
Swati Modi¹, Yona Cloonan², Danielle Goudeau³, Donald M. Jones⁴, Christine L. Amity⁵, Lynne M. Frydrych⁴, Kelly A. Reckley⁶, Heather Eng⁷, Stephen R. Wisniewski⁸, Larry W. Moreland⁹ and Marc C. Levesque³, ¹Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology & Clinical Immun, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ⁵Rheumatology & Clinical Immun, Univ of Pittsburgh, Pittsburgh, PA, ⁶Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁷Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁸Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁹Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) positive rheumatoid arthritis (RA) patients develop more extra-articular disease manifestations and erosions, and have a worse…
Abstract Number: 2128 • 2012 ACR/ARHP Annual Meeting
Matrix Metalloproteinase 3: A Biomarker of Disease Activity in Rheumatoid Arthritis
Sandra Reuter¹, Torsten Matthias² and Bruno Larida³, ¹AIRA e.V., AESKU.KIPP Institute, Wendelsheim, Germany, ²AESKU.Diagnostics GmbH & Co. KG, Wendelsheim, Germany, ³AESKU.DIAGNOSTICS INC, Oakland, CA
Background/Purpose: New biomarkers for monitoring Rheumatoid Arthritis (RA) disease activity and prognosis of progression are urgently needed to individually optimize drug therapy and prevent joint…
Abstract Number: 2129 • 2012 ACR/ARHP Annual Meeting
Dickkopf-1 Is Increased in Rheumatoid Arthritis of Recent Onset and Might Be a New Biomarker of Structural Progression. Data From the Espoir Cohort
Raphaèle Seror¹, Stephan Pavy², Thierry Schaeverbeke³, Alain Saraux⁴, Xavier Mariette⁵ and Corinne Miceli-Richard¹, ¹Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, ²Hopital Bicetre, Paris, France, ³Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ⁴Rhumatologie, CHU de la Cavale Blanche, Brest Cedex, France, ⁵Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: Dickkopf-1 (DKK-1) is an inhibitory protein of the Wnt signalling pathway that could be involved in subchondral bone erosions occurring in rheumatoid arthritis (RA).…
Abstract Number: 2130 • 2012 ACR/ARHP Annual Meeting
Studies of Disease and Therapy-Response Biomarkers in Early Rheumatoid Arthritis Treated with Methotrexate
Aase Haj Hensvold¹, Saedis Saevarsdottir*², Wanyiang Li*³, Vivianne Malmström⁴, Guy Cavet⁵, Lars Klareskog⁶ and Anca Catrina¹, ¹Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ²Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Crescendo Bioscience Inc. 341 Oyster Point Blvd South San Francisco, CA 94080, San Francisco, CA, ⁴Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Crescendo Bioscience Inc., South San Francisco, CA, ⁶Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden
*equally contributed Background/Purpose: To identify disease and therapy response serum biomarkers in early untreated RA patients started on methotrexate as the only DMARD. Methods: 186…
Abstract Number: 2131 • 2012 ACR/ARHP Annual Meeting
An Evaluation of Prognostic Factors for Orthopaedic Joint Surgery in Rheumatoid Arthritis. Results From Two Multicentre UK Inception Cohorts (1986-2011)
Elena Nikiphorou¹, Lewis Carpenter², Sam Norton³, David James⁴, Patrick D. Kiely⁵, David Walsh⁶, Richard Williams⁷ and Adam Young³, ¹Research Department of Epidemiology & Public Health, UCL and Rheumatology Department, St Albans City Hospital, ERAS, St Albans City Hospital & University College London (UCL), London, United Kingdom, ²Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, United Kingdom, ³Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom, ⁴Rheumatology, Diana Princess of Wales Hospital, Grimsby, United Kingdom, ⁵Rheumatology Dept, St. Georges Hospital, London, United Kingdom, ⁶Academic Rheum/Clin Sci Bldg, City Hospital, Nottingham, United Kingdom, ⁷Rheumatology, County Hospital, Hereford, United Kingdom
Background/Purpose: The need for orthopaedic surgery in Rheumatoid Arthritis (RA) is the result of failed medical treatment and a surrogate marker for joint destruction. Reliable…
Abstract Number: 2132 • 2012 ACR/ARHP Annual Meeting
Disease Activity and Anti-CCP Status, but Not Sociodemographic Factors or Patient Comorbidities, Affect Time to Diagnosis in Early Rheumatoid Arthritis
Cheryl Barnabe¹, Juan Xiong², Gilles Boire³, Carol A. Hitchon⁴, Boulos Haraoui⁵, Janet E. Pope⁶, J. Carter Thorne⁷, Edward Keystone⁸, Diane Tin⁹, Vivian P. Bykerk¹⁰ and Canadian ArThritis CoHort¹¹, ¹Medicine, Community Health Sciences, University of Calgary, Calgary, AB, Canada, ²University of Toronto, Toronto, Canada, ³Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada, ⁵Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁶Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Toronto
Background/Purpose: Delays in patient presentation to primary care providers, subsequent referral for rheumatology assessment, and recognition of rheumatoid arthritis (RA) by the rheumatologist increase time…
Abstract Number: 2133 • 2012 ACR/ARHP Annual Meeting
Relationship Between Clinical Response and Radiographic Outcomes in Patients with Moderate Rheumatoid Arthritis
Josef S. Smolen¹, Ronald F. van Vollenhoven², Andrew S. Koenig³, Ronald Pedersen³, Annette Szumski⁴ and Eustratios Bananis⁴, ¹Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Unit for Clinical Trial Therapy research, The Karolinska Institute, Stockholm, Sweden, ³Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Specialty Care, Pfizer Inc., Collegeville, PA
Background/Purpose: Clinical evidence has established the importance of early, intensive treatment of rheumatoid arthritis (RA) to decrease disease activity and prevent joint damage.1 The objective…
Abstract Number: 2134 • 2012 ACR/ARHP Annual Meeting
The Changed Prognosis of Patients with Early Rheumatoid Arthritis
Karin Britsemmer¹ and Dirkjan van Schaardenburg², ¹Rheumatology, Jan van Breemen Research Institute / Reade, Amsterdam, Netherlands, ²Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
The Changed Prognosis of Patients with Early Rheumatoid Arthritis Background/Purpose: The treatment of rheumatoid arthritis (RA) has changed greatly during the past fifteen to twenty…
Abstract Number: 2135 • 2012 ACR/ARHP Annual Meeting
Trabecular Bone Texture parameters are Correlated with Magnetic Resonance Imaging (MRI) bone Edema At Hand and Wrist in Active Rheumatoid Arthritis (RA)
Thao Pham¹, Sophie Trijau¹, Roland Chapurlat², Damien Loeuille³, Thierry Schaeverbeke⁴, Christian Roux⁵, Claude-Laurent Benhamou⁶, Olivier Vittecoq⁷, Jean Sibilia⁸, Frederic Mistretta⁹ and Cécile Hacquard-Bouder¹⁰, ¹Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, ²Hôpital Edouard Herriot, Lyon, France, ³Rheumatology, CHU Brabois, Vandoeuvre les Nancy, France, ⁴Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ⁵Rheumatology, Paris Descartes University, Paris, France, ⁶Centre Hospitalier Régional d'Orléans, Orleans, France, ⁷Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, ⁸Rheumatology, CHU Hautepierre, Strasbourg, France, ⁹Lyon, France, ¹⁰Abbott France, Rungis, France
Background/Purpose: In RA, bone marrow edema (BME) is predictive of erosive progression. Bone erosions are assumed to appear through activation of local bone resorption mechanisms,…
Abstract Number: 2136 • 2012 ACR/ARHP Annual Meeting
Alcohol Use and Radiographic Disease Progression in African Americans with Recent Onset Rheumatoid Arthritis
Marshall Davis¹, Kaleb Michaud¹, Harlan Sayles¹, Doyt L. Conn², Larry W. Moreland³, S. Louis Bridges Jr.⁴ and Ted R. Mikuls¹, ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, Emory Univ School of Medicine, Atlanta, GA, ³Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Previous studies have shown that alcoholic beverage consumption can modify levels of circulating inflammatory cytokines and alter expression of innate immune system receptors. Recognizing…
Abstract Number: 2137 • 2012 ACR/ARHP Annual Meeting
Contribution of Disease Activity, Joint Damage and Comorbidity to Impairment (SOFI) and Disability (HAQ) in Rheumatoid Arthritis Patients Over 20 Years
Meliha C. Kapetanovic¹, Elisabet Lindqvist², Jan-Åke Nilsson³, Pierre Geborek⁴, Tore Saxne⁵ and Kerstin Eberhardt⁶, ¹Dept of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, ²Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund University, Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁵Section of Rheumatology, Deparment of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁶Department of Clinical Sciences Lund, Section of Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden, Lund, Sweden
Background/Purpose: To study the contribution of disease activity, joint damage and co-morbidity on development of impairment measured by signals of functional impairment (SOFI) and disability…
Abstract Number: 2138 • 2012 ACR/ARHP Annual Meeting
Racial and Ethnic Disparities in Rheumatoid Arthritis Outcomes in Community-Based U.S. Rheumatology Practices: Results From the Consortium of Rheumatology Researchers of North America Registry
Jeffrey D. Greenberg¹, Tanya Spruill², Gbenga Ogedebe³, Joel M. Kremer⁴, Ying Shan⁵, Katherine C. Saunders⁶, Yusuf Yazici⁷ and Leslie R. Harrold⁵, ¹NYU Hospital for Joint Diseases, New York, NY, ²Center for Healthful Behavior Change, Department of Population Health, NYU School of Medicine, New York, NY, ³New York University School of Medicine, New York, NY, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY, ⁵Dept of Medicine, UMass Medical School, Worcester, MA, ⁶Corrona, LLC., Southborough, MA, ⁷New York University, New York, NY
Background/Purpose: Disparities in medication use and clinical outcomes have been reported in patients with rheumatoid arthritis (RA) and other chronic diseases. However, there is little…
Abstract Number: 2139 • 2012 ACR/ARHP Annual Meeting
Smoking Is Associated with Worsening Functional Status Over Time in a Diverse Cohort of Patients with Rheumatoid Arthritis
Matthew Reimert¹, Laura Trupin², Patricia P. Katz³, Edward H. Yelin⁴, Jennifer Barton² and John B. Imboden⁵, ¹Rheumatology, University of CA San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³Medicine, University of California San Francisco, San Francisco, CA, ⁴Medicine, UC San Francisco, San Francisco, CA, ⁵Department of Medicine, Division of Rheumatology, UCSF, San Francisco, CA
Background/Purpose: Although the effects of tobacco use on disease onset, severity, and response to therapy have been well studied in rheumatoid arthritis (RA), there is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].